Keros Therapeutics Stock
Keros Therapeutics, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Jasbir S. Seehra
- Employees
- 92
- Market cap
- $211 M
- IPO
- 08/04/2020
Keros Therapeutics, Inc., a biopharmaceutical entity in the clinical development phase, is focused on pioneering and commercializing innovative therapies for individuals afflicted by hematological and musculoskeletal conditions that currently lack adequate treatment options. Its flagship protein therapeutic, KER-050,…
Keros Therapeutics stock: price history
1D
-4.0%
1W
-10.8%
1M
-0.7%
6M
-8.7%
YTD
-47.6%
1Y
-22.4%
2Y
-82.9%
5Y
-72.7%
10Y
–
Next earnings date
Next earnings date
04/11/2026 (in 18 days)
Volatility around earnings
~14% weaker price swings than usual
Ask the agents about Keros Therapeutics
Analyst assessment of Keros Therapeutics
PRICE TARGET LOW
US$18.00
CONSENSUS
US$20.33
MEDIAN
US$20.00
PRICE TARGET HIGH
US$23.00
0
STRONG BUY
10
BUY
7
HOLD
0
SELL
0
STRONG SELL
17
TOTAL · Buy
As of: 04/08/2026
Keros Therapeutics stock metrics
P/E
-2.88
P/B
0.8
EV/EBITDA
0.36
RETURN ON EQUITY
-10.9%
NET MARGIN
0.0%
DEBT/EQUITY
0.06
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
91.6%
FLOAT SHARES
18,152,674
AVG. DAILY VOLUME (30D)
184,616
Insider transactions (SEC)
Tanini Annita
Cho Esther
Lerner Lorena Raquel
Newton Charles W.
BIENAIME JEAN JACQUES
Institutional holders
Comparable stocks
Frequently asked questions about Keros Therapeutics stock
What does Keros Therapeutics do?
Keros Therapeutics, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Jasbir S. Seehra, the company employs around 92 people.
The IPO was on 08/04/2020; the stock trades on NASDAQ under the ticker KROS.
What do analysts say about Keros Therapeutics stock?
17 analysts rate the stock, the consensus is Buy (as of 04/08/2026).
The average price target is US$20.33, ranging from US$18.00 to US$23.00, with a median of US$20.00.
This is an external assessment, not a statement by Market Jury.
When does Keros Therapeutics report next?
The next earnings date is 04/11/2026.
Around past earnings, price swings were roughly -14% stronger than usual.
Does Keros Therapeutics pay a dividend?
No, Keros Therapeutics currently does not pay a dividend.
Which stocks are comparable to Keros Therapeutics?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Keros Therapeutics stock analyzed?
Clicking "Analyze stock" lets five strategies assess Keros Therapeutics against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.